Prevention and Treatment of Osteoporosis with Traditional Chinese Medicine Gushukang
Jing Wang, Ji-Su Xue, Rui-Hao Zhang
Journal of Pharmaceutical Research International · pp. 3608–3613 · Published 28 Dec 2021
10.9734/jpri/2021/v33i60B35054Abstract
As our population continues to age, osteoporosis is becoming more common and burdensome for society. Its treatment is troublesome because its mechanism is complicated and easily hidden behind other ailments and symptoms. In addition, the adverse effect of traditional therapeutic drugs for osteoporosis is another puzzle for both clinicians and patients. The Traditional Chinese Medicine (TCM) known as Gushukang (GSK) has a long history in treating osteoporosis. However, because the formulation of GSK consists of multiple plant products, it is difficult to determine its proper purity, efficacy, dosage, and safety as required by modern medicine. Still, researchers have begun to use modern scientific tools to investigate GSK for treating osteoporosis. Following the inclusion of TCM in the latest International Statistical Classification of Diseases and Related Health Problems (ICD-11, 2019) by the WHO and recent elucidation of the therapeutic mechanisms of GSK in treating diseases, it has been demonstrated that GSK does indeed show potential for treating osteoporosis in the future. This review summarizes recent advances surrounding GSK for the treatment of osteoporosis in both laboratory animals and humans, from complex formulae to single ingredients.
Cited by 0
No indexed citations yet.
Related research
- Outcome of Pedicle Screw Fixation in Patients with Clinically Suspected Osteoporosis at the National Orthopaedic Hospital Dala Kano Nigeria — shares topic coverage
- Effects of Different Calcium Compounds on Bone Health — shares topic coverage
- The Relationship between Homocysteine and Fragility Fractures - A Systematic Review — shares topic coverage
- Students Calcium Awareness Program: A Proposal of Mobile Devices Health Promotion Program — shares topic coverage
- Efficacy of Neridronic Acid IV and IM in Improving BMD and Reducing Fracture Risk in Postmenopausal Osteoporosis — shares topic coverage
Article metrics
Real usage data collected on this platform.
8
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.